Síndrome de abstinência em Unidade de Tratamento Intensivo Pediátrico: protocolo de revisão sistemática / Abstinence syndrome in Pediatric Intensive Care Unit: a systematic review protocol

OBJETIVO: Verificar qual o tratamento mais indicado para a prevenção e redução dos sinais e sintomas de abstinência em crianças criticamente doentes por meio de uma revisão sistemática da literatura mundial. MÉTODO: A revisão sistemática será conduzida conforme a metodologia PRISMA e Cochrane, com registro no PROSPERO, sob o número de ID CRD42021274670, nas respectivas bases de dados PubMed, LILACS, Embase, Web of Science, Cochrane, CINAHL, Cochrane Database Systematic Review e CENTRAL. As buscas serão realizadas por dois avaliadores independentes, um terceiro realizará o intermédio se necessário. Os dados serão inseridos no programa de software Zotero que irá excluir os artigos duplicados, após o material selecionado será transferido para planilha Excel em instrumento próprio. Os estudos serão classificados quanto ao seu nível de evidência, viés e fator de risco. Os resultados serão analisados e tabulados e discutidos a fim de melhor compreensão dos resultados. Se possível, serão realizadas meta-análises para os resultados agregados.

OBEJECTIVE: To verify the most appropriate treatment for the prevention and reduction of the signs and symptoms of abstinence in critically ill children through a systematic review of the world literature. METHOD: The systematic review will be conducted according to the PRISMA and Cochrane methodology, with registration at PROSPERO, under the ID number CRD42021274670, in the respective databases, PUBMed, LILACS, Embase, Web of Science, Cochrane, CINAHL, Cochrane Database Systematic Review, and CENTRAL, searches will be carried out by two independent evaluators, and a third party will perform the intermediate if necessary. The data will be entered into the Zotero software program that will delete duplicate articles after the selected material is transferred to an Excel spreadsheet on its instrument. The studies will be classified according to their level of evidence, bias, and risk factors. The results will be analyzed, tabulated, and discussed to understand the results better. If possible, meta-analyzes will be carried out for the aggregated results.

Zolpidem dependence and withdrawal. A case report of generalized seizures.

Zolpidem is a non-benzodiazepine hypnotic agent used most frequently in the treatment of insomnia, indicated for short-term use. It is not indicated for the chronic treatment of sleep disorders, despite which there is evidence in clinical practice that a large number of patients receive it for years. Although it has been described that it presents a better profile of adverse effects than benzodiazepines and that it generates a lower risk of dependence and withdrawal than these, there are significant reports of cases of dependence and withdrawal from zolpidem. A report of a case of generalized tonic-clonic seizures due to withdrawal at a dose of 300 mg per day of zolpidem is presented and a brief review of the literature is carried out.

Dependencia y abstinencia de Zolpidem. Reporte de un caso de convulsiones generalizadas

El zolpidem es un agente hipnótico no benzodiacepínico utilizado con suma frecuencia en el tratamiento del insomnio e indicado para emplearlo en el corto plazo. No está indicado para el tratamiento crónico de los trastornos del sueño, pese a lo cual se evidencia en la práctica clínica que gran cantidad de pacientes lo reciben por arios. Si bien se ha descrito que presenta un mejor perfil de efectos adversos que las benzodiacepinas y que genera menos riesgo de dependencia y abstinencia que estas, existen sendos reportes de casos de dependencia y abstinencia de zolpidem. Se presenta el reporte de un caso de convulsiones tónico-clónicas generalizadas por abstinencia a dosis de 300 mg/día de Zolpidem y se realiza una breve revisión de la literatura.

Zolpidem is a non-benzodiazepine hypnotic agent used most frequently in the treatment of insomnia, indicated for short-term use. It is not indicated for the chronic treatment of sleep disorders, despite which there is evidence in clinical practice that a large number of patients receive it for years. Although it has been described that it presents a better profile of adverse effects than benzodiazepines and that it generates a lower risk of dependence and withdrawal than these, there are significant reports of cases of dependence and withdrawal from zolpidem. A report of a case of generalized tonic-clonic seizures due to with drawal at a dose of 300 mg per day of zolpidem is presented and a brief review of the literature is carried out.

Lactancia materna y alojamiento en el abordaje del síndrome de abstinencia neonatal. Revisión panorámica / Breastfeeding and rooming-in in the management of neonatal abstinence syndrome. Scoping review

En la actualidad, el aumento del consumo de drogas en gestantes está provocando un incremento del síndrome de abstinencia neonatal (SAN). El abordaje de dicho síndrome varía en la práctica clínica y, en algunos centros, se tiende a suspender tanto la lactancia materna como el alojamiento conjunto. El objetivo de este trabajo es analizar los efectos de la lactancia materna y el alojamiento conjunto en neonatos con SAN mediante la realización de unarevisión panorámica de trabajos publicados en PubMed y CINAHL. Según los once trabajos incluidos, tanto la lactancia materna como el alojamiento conjunto reducen la estancia hospitalaria, así como la necesidad y la duración del tratamiento farmacológico. Además, el alojamiento conjunto disminuye la probabilidad de admisión en Cuidados Intensivos Neonatales, aunque no mejoró la severidad de los signos del SAN. Los bebes alimentados con lactancia materna presentaron signos significativamente más leves de abstinencia y, una mayor probabilidad, aunque no significativa, de ser reingresados. No hay evidencia de que el alojamiento conjunto disminuya la readmisión hospitalaria tras el alta. Los hallazgos justifican que tanto la cohabitación como la lactancia se deberían mantener siempre que sea posible en el abordaje de este síndrome para no empeorar las condiciones del neonato, tomando las medidas oportunas para garantizar la seguridad del niño y de la madre.(AU)

At present, more babies are born with neonatal abstinence syndrome due to the increased use of certain substances by their mothers while pregnant. The therapeutic approaches for this syndrome vary in clinical practice, and in some centres, breastfeeding and roomingin are interrupted. The aim of this work was to analyse the effects of breastfeeding and roomingin in infants with neonatal abstinence syndrome by conducting a scoping review of the related literature in PubMed and CINAHL. Eleven papers were included, which showed that breastfeeding and roomingin reduced hospital stay and the need for and duration of pharmacological treatment. In addition, roomingin decreased the likelihood of admission to the Neonatal Intensive Care Unit, although there was no improvement of the severity of neonatal abstinence syndrome signs. Breastfed infants had milder withdrawal signs and, although they were more likely to be readmitted than formulafed infants were, there were no statistically significant differences. There was no evidence that roomingin decreased hospital readmission after discharge. Our findings support the maintenance of cohabitation and breastfeeding whenever possible in the management of this neonatal abstinence syndrome, so as not to worsen the conditions of the neonate, while introducing measures to ensure motherchild safety.(AU)

Tiaprida, una alternativa de tratamiento en el trastorno por uso de alcohol: a propósito de un caso / Tiapride, an alternative treatment in alcohol use disorder: a case report

Objetivo: Exponer a través de un caso clínico el uso de tiaprida para la desintoxicación de alcohol en un paciente con diagnóstico de trastorno por consumo de alcohol grave 303.90 (F10.20).Caso clínicoUna mujer de 50 años, en seguimiento en la Unidad de Conductas Adictivas desde septiembre de 2016 hasta la actualidad, con diagnósticos de trastorno de adaptación 309.4 (F43.25) con alteración mixta de las emociones o de la conducta, trastorno por consumo de alcohol grave 303.90 (F10.20) y descompensación maniforme, al cual se le instaura el tratamiento con tiaprida.ResultadosLos estudios consultados demuestran la eficacia y seguridad de tiapride para el síndrome de abstinencia a alcohol tanto en ámbito ambulatorio como hospitalario, en monoterapia o en politerapia con benzodiacepinas y/o antiepilépticos, siendo usado también en la agitación y/o la sintomatología psicótica.ConclusionesSe ha observado que en el síndrome de abstinencia a alcohol la tiaprida es eficaz, pudiendo incluso tenerlo en cuenta como tratamiento coadyuvante a benzodiacepinas o anticonvulsivantes. Con vistas a futuro, se deberían tener en cuenta la farmacogenética que afectan al trastorno por consumo de alcohol, con lo que se podría beneficiar de menores efectos adversos una terapia personalizada individualizada. (AU)

Objective: Present a clinical case report on the use of tiapride for alcohol detoxification in a patient with a diagnosis of severe alcohol use disorder 303.90 (F10.20).Clinical case report50 year-old female, under follow-up in the Addictive Behavior Unit from September 2016 to present, with diagnoses of adjustment disorder 309.4 (F43.25)Mixed disturbance of emotions or behavior, severe alcohol use disorder 303.90 (F10.20) and severe decompensation, who is treated with tiapride.ResultsThe studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, being also used in agitation and/or psychotic symptomatology.ConclusionsIn alcohol withdrawal syndrome, tiapride has been found to be effective and can even be considered as an adjunctive treatment to benzodiazepines or anticonvulsants. With a view to the future, pharmacogenetics affecting alcohol use disorder should be taken into account, so that individualized personalized therapy could benefit from fewer adverse effects. (AU)

Frecuencia de consumo de drogas adictivas ilícitas en gestantes o puérperas y su detección en recién nacidos en un hospital materno-infantil de Asunción

Introducción: la adicción a sustancias ilícitas constituye un problema de salud pública, del cual no están exentas las embarazadas. Los efectos deletéreos sobre el feto pueden tener consecuencias catastróficas. Objetivo: Determinar la frecuencia de uso de drogas ilícitas en mujeres gestantes y caracterizar a estas mujeres y sus recién nacidos de julio de 2020 a julio de 2021. Material y método: Estudio transversal, descriptivo, observacional con madres con sospecha de uso de drogas y sus recién nacidos (RN). Se buscó asociación entre variables estudiadas. Se utilizó escala de Finnegan para síndrome de abstinencia neonatal (SAN) y se determinó presencia de drogas en orina. Resultados: Fueron incluidos 107 binomios madres -hijos. Prevalencia de madres adictas de 11,42%. Edad promedio de madres 24,5 años y 29,9% en situación calle. 70% fueron partos vaginales, 90,5% con APGAR de 7-10. 26,1% fueron RN prematuros. RCIU 34,5%, PEG 35,5%. 93,3% mujeres se autorreportó como consumidora, 57,9% tuvo control prenatal nulo. 56% de gestantes presentó signos evidentes de ser consumidora de drogas ilícitas al ingreso. La droga más consumida fue la cocaína (COC) 85%. Detección de cocaína en RN fue 81,3%. SAN en 24,2% RN. Se encontró Cocaína en la orina de 18/26 de los pacientes con SAN, y en 64/77 de los pacientes sin síndrome de abstinencia. Tuvo Lues el 25,9%. Se encontró asociación de SAN con la presencia de COC en el RN. Conclusiones: el consumo de drogas en la embarazada expone al RN a drogas deletéreas, siendo la droga más frecuentemente consumida la COC. La prevalencia de SAN fue baja, encontrándose asociación entre esta entidad y la presencia de COC en RN.

Introduction: Addiction to illicit substances constitutes a public health problem, from which pregnant women are not exempt. The deleterious effects on the fetus can have catastrophic consequences. Objective: To determine the frequency of illicit drug use in pregnant women and to characterize these women and their newborns during the time period from July 2020 to July 2021. Materials and methods: this was a cross-sectional, descriptive, observational study with mothers suspected of drug use and their newborns (NBs). An association was sought between the studied variables. The Finnegan scale for neonatal abstinence syndrome (NAS) was used and the presence of drugs in urine was determined. Results: 107 mother-child pairs were included. The prevalence of addicted mothers was 11.42%. Average age of mothers was 24.5 years and 29.9% were living on the street. 70% were vaginal deliveries, 90.5% with an APGAR score of 7-10. 26.1% were premature newborns. IUGR 34.5%, SGA 35.5%. 93.3% women self-reported as drug consumers, 57.9% had zero prenatal control. 56% of pregnant women presented obvious signs of being an illicit drug user upon admission. The most consumed drug was cocaine (COC), 85%. Detection of cocaine in newborns was 81.3%. NAS was diagnosed in 24.2% NB. Cocaine was found in the urine of 18/26 of the patients with NAS, and in 64/77 of the patients without withdrawal syndrome. 25.9% had Lues. An association of NAS with the presence of COC in the newborn was found. Conclusions: drug use in pregnant women exposes the newborn to deleterious drugs, COC being the most frequently used drug. The prevalence of NAS was low, although we found an association between NAS and the presence of COC in newborns.

Severe irritability in a critically ill preterm infant: a case of delirium at the neonatal intensive care unit / Grave irritabilidade em prematuro criticamente doente: um caso de delirium na unidade de terapia intensiva neonatal

ABSTRACT Delirium is a common disorder in intensive care units, being associated with greater morbidity and mortality. However, in neonatal intensive care units, delirium is rarely diagnosed, due to the low familiarity of the neonatologist with the subject and the difficulties in the applicability of diagnostic questionnaires. This case report aimed to assess the presence of this disorder in this group of patients and identify the difficulties encountered in the diagnosis and treatment. We report the case of a premature newborn with necrotizing enterocolitis during hospitalization and underwent three surgical approaches. The newborn exhibited intense irritability, having received high doses of fentanyl, dexmedetomidine, clonidine, ketamine, phenytoin, and methadone, without the control of the symptoms. A diagnosis of delirium was then made and treatment with quetiapine was started, with a complete reversal of the symptoms. This is the first case reported in Brazil and the first describing the withdrawal of the quetiapine.

RESUMO Delirium é uma síndrome comum em unidades de terapia intensiva, associando-se a maiores morbidade e mortalidade. No entanto, nas unidades de terapia intensiva neonatal, ele raramente é diagnosticado em razão da baixa familiaridade do neonatologista com a suspeita diagnóstica e das dificuldades na aplicabilidade dos questionários diagnósticos. Este relato de caso tem como objetivos mostrar que delirium está presente nesse grupo de pacientes e apontar as dificuldades encontradas no seu diagnóstico e tratamento. Relatamos o caso de um recém-nascido prematuro com enterocolite necrosante, submetido a três abordagens cirúrgicas. O recém-nascido apresentou intensa irritabilidade, tendo recebido altas doses de fentanil, dexmedetomidina, clonidina, cetamina, fenitoína e metadona, sem controle dos sintomas. Em seguida, foi feita a hipótese diagnóstica de delirium e iniciado tratamento com quetiapina, com reversão completa dos sintomas. Este é o primeiro caso notificado no Brasil e o primeiro que descreve a suspensão da quetiapina.

Síndrome de abstinencia asociado al uso recreativo de fentanilo: serie de dos casos / Withdrawal syndrome associated with recreational use of fentanyl: case series

El abuso de sustancias como los opioides ha venido en aumento durante la última década, siendo responsable de gran número de muertes en Estados Unidos. El consumo especialmente de fentanilo se ha convertido en una epidemia que afecta la salud pública y el bienestar socioeconómico de algunos países. Colombia no es ajena a este panorama, y en los últimos años se han descrito casos de consumo de fentanilo como droga de abuso. En este artículo se presentarán dos reportes de casos de uso de fentanilo recreativo parenteral que desarrollaron síndrome de abstinencia y requirieron manejo intrahospitalario en la ciudad de Medellín-Colombia. (AU)

The abuse of substances such as opioids has been increasing over the last decade, being responsible for a large number of deaths in the United States. The consumption, especially of fentanyl, has become an epidemic that affects public health and the socioeconomic well-being of some countries. Colombia is no stranger to this panorama; in recent years, cases of fentanyl consumption as a drug of abuse have been described. In this article, two case reports of parenteral recreational fentanyl use that developed withdrawal syndrome and required in-hospital management in the city of Medellín-Colombia will be presented. (AU)

Estratégias para manejo e prevenção da síndrome de abstinência em pacientes pediátricos críticos: revisão sistemática / Strategies for the management and prevention of withdrawal syndrome in critically ill pediatric patients: a systematic review

RESUMO Objetivo: Verificar as estratégias de prevenção e tratamento da síndrome de abstinência em unidade de terapia intensiva pediátrica. Métodos: Trata-se de revisão sistemática nas bases de dados PubMed®, Lilacs, Embase, Web of Science, Cochrane, Cinahl, Cochrane Database Systematic Review e CENTRAL. Uma estratégia de busca em três etapas foi utilizada para esta revisão. O protocolo da revisão foi aprovado no PROSPERO (CRD42021274670). Resultados: Foram incluídos na análise 12 artigos. Observou-se grande heterogeneidade entre os estudos incluídos, principalmente em se tratando de esquemas terapêuticos utilizados na sedação e na analgesia. As doses de midazolam variaram de 0,05mg/kg/hora a 0,3mg/kg/hora. A morfina também variou consideravelmente, de 10mcg/kg/hora a 30mcg/kg/hora entre os estudos. A escala mais utilizada para identificação da síndrome de abstinência, entre os 12 estudos selecionados, foi a Sophia Observational Widrawal Symptoms Scale. Em três estudos, houve diferença estatística relevante na prevenção e no manejo da síndrome de abstinência com a implantação de protocolos (p < 0,01 e p < 0,001). Conclusão: Observou-se grande variação entre o regime de sedoanalgesia utilizado entre os estudos e o método de desmame e avaliação de síndrome de abstinência. São necessários mais estudos para fornecer evidências mais robustas acerca do tratamento mais indicado para prevenção e redução dos sinais e sintomas de abstinência em crianças criticamente doentes. Registro PROSPERO:CRD 42021274670

ABSTRACT Objective: To verify strategies for the prevention and treatment of abstinence syndrome in a pediatric intensive care unit. Methods: This is a systematic review in the PubMed database®, Lilacs, Embase, Web of Science, Cochrane, Cinahl, Cochrane Database Systematic Review and CENTRAL. A three-step search strategy was used for this review, and the protocol was approved in PROSPERO (CRD42021274670). Results: Twelve articles were included in the analysis. There was great heterogeneity among the studies included, especially regarding the therapeutic regimens used for sedation and analgesia. Midazolam doses ranged from 0.05mg/kg/hour to 0.3mg/kg/hour. Morphine also varied considerably, from 10mcg/kg/hour to 30mcg/kg/hour, between studies. Among the 12 selected studies, the most commonly used scale for the identification of withdrawal symptoms was the Sophia Observational Withdrawal Symptoms Scale. In three studies, there was a statistically significant difference in the prevention and management of the withdrawal syndrome due to the implementation of different protocols (p < 0.01 and p < 0.001). Conclusion: There was great variation in the sedoanalgesia regimen used by the studies and the method of weaning and evaluation of withdrawal syndrome. More studies are needed to provide more robust evidence about the most appropriate treatment for the prevention and reduction of withdrawal signs and symptoms in critically ill children. PROSPERO register: CRD 42021274670

Recién nacidos hijos de madres adictas. Formas de presentación: no todo se trata de síndrome de abstinencia

RESUMEN El consumo de drogas ilegales por la mujer gestante puede ocasionar morbilidades potencialmente graves en el feto y recién nacido. Las manifestaciones en el niño pueden ser diversas, por lo que es necesario un alto índice de sospecha a fin de realizar el diagnóstico y tratamiento apropiados. Se presentan tres casos de recién nacidos, hijos de madres adictas, con variadas expresiones clínicas.

ABSTRACT Illegal drug consumption by pregnant women can cause potentially serious morbidities in the fetus and newborn. Manifestations in children can be diverse, so a high index of suspicion is necessary in order to appropriately diagnose and treat this condition. Three cases of newborns, born to mothers with substance-abuse disorder, with various clinical presentations are reviewed.

Tiapride, una alternativa de tratamiento para el trastorno por el uso de alcohol: a propósito de un caso / Tiapride, an alternative treatment for alcohol use disorder: a case report

Objetivo: Exponer a través de un caso clínico el uso de tiapride para la desintoxicación de alcohol en un paciente con diagnóstico de trastorno por el uso de alcohol.Caso clínicoUna mujer de 50 años, en seguimiento en la Unidad de Conductas Adictivas desde septiembre de 2016 hasta la actualidad, con diagnósticos de trastorno de adaptación con alteración mixta de las emociones, trastorno por consumo de alcohol y descompensación maniforme, ante lo cual se le instaura el tratamiento con tiapride.ResultadosLos estudios consultados demuestran la eficacia y seguridad de tiapride para el síndrome de abstinencia al alcohol, tanto en el ámbito ambulatorio como hospitalario, en monoterapia o en politerapia con benzodiacepinas y/o antiepilépticos, siendo usado también en la agitación y/o sintomatología psicótica.ConclusionesEn el síndrome de abstinencia al alcohol se ha observado que el tiapride es eficaz, pudiendo incluso tenerlo en cuenta como un tratamiento coadyuvante a las benzodiacepinas o los anticonvulsivantes. Con vistas al futuro, se deberían tener en cuenta la farmacogenética que afecta al trastorno por consumo de alcohol, con lo que se podría beneficiar, con menores efectos adversos, a una terapia personalizada individualizada. (AU)

Objective: To present a case report on the use of tiapride for alcohol detoxification in a patient diagnosed with alcohol use disorder.Clinical caseA 50-year-old woman, under follow-up in the Addictive Behaviour Unit from September 2016 to date, with a diagnosis of adjustment disorder with mixed emotional disturbance, alcohol use disorder and mood decompensation, for which treatment with tiapride was initiated.ResultsThe studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome, in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, and used for agitation and/or psychotic symptoms.ConclusionsTiapride has been found to be effective in alcohol withdrawal syndrome and could even be considered adjunctive treatment to benzodiazepines or anticonvulsants. Looking to the future, pharmacogenetics affecting alcohol use disorder should be considered, and this could result in tailored, personalised therapy, with fewer adverse effects. (AU)

Adaptação cultural da withdrawal assesment tool version (wat ­ 1) para língua portuguesa falada no Brasil / Adaptación cultural de la evaluación de retiro versión de la herramienta (wat ­ 1) para el idioma portugués hablado en Brasil / Cultural adaptation of the version of the withdrawal assessement tool (wat-1) for portuguese language spoken in Brazil

Objetivo: Adaptar, para a língua portuguesa do Brasil, o instrumento Withdrawal Assessment Tool Version (WAT ­1). Métodos: Pesquisa metodológica, realizada no município de São Paulo/SP de março de 2017 a abril de 2019. O processo de adaptação cultural obedeceu às dez etapas definidas segundo o Report of the ISPOR Task Force for Translation and CulturalAdaptation, sendo realizado avaliação das equivalências semântica, idiomáticas, conceitual e cultural, por um comitê de nove juízes; avaliação da compreensibilidade do instrumento por 30 especialistas em Terapia Intensiva Pediátrica; revisão da avaliação da compreensibilidade; revisão final da tradução; relatório final. Resultados: A concordância entre os juízes na análise das equivalências apresentou escore médio de 96,9% na segunda rodada, devido a concordância de 80% na primeira etapa. Já, na avaliação da compreensibilidade, obteve-se 100% de compreensão dos especialistas. Conclusão: A tradução e adaptação cultural do instrumento wat-1 para língua portuguesa falada no Brasil foram consideradas satisfatórias(AU)

Objective: To adapt the Withdrawal Assessment Tool Version (WAT - 1) to the Portuguese language of Brazil. Methods: Methodological research, carried out in the city of São Paulo/SP from March 2017 to April 2019. The process of cultural adaptation followed the ten stages defined according to the Report of the ISPOR Task Force for Translation and Cultural Adaptation: authorization; translation, reconciliation, backtranslation; back-translation review; harmonization, with the evaluation of semantic, idiomatic, conceptual and cultural equivalences carried out by a committee of nine judges; evaluation of the comprehensibility of the instrument by 30 specialists in Pediatric Intensive Care TIP; review of the comprehensibility assessment; final translation review; final report. Results: The adapted instrument was divided into 35 sentences, being evaluated by nine judges regarding their equivalences. The agreement among the judges in the analysis of equivalences proved to be excellent, with an average score of 96.9% in these cond round. There was a need for two rounds, as some items did not show 80% agreement in the first stage. In the comprehensibility assessment, 100% of the specialists' understanding was obtained. Conclusion: The translation and cultural adaptation of the wat-1 instrument to the Portuguese language spoken in Brazil were considered satisfactory.(AU)

Objetivo: Adaptar la Versión de la Herramienta de Evaluación de Retiros (WAT - 1) al idioma portugués de Brasil. Métodos: Investigación metodológica, realizada en la ciudad de São Paulo/SP de marzo de 2017 a abril de 2019. Cuyo proceso de adaptación cultural siguió las diez etapas definidas según el Informe del Grupo de Trabajo ISPOR para la Traducción y Adaptación Cultural: autorización; traducción, reconciliación, retrotraducción; revisión de la retrotraducción; armonización, con la evaluación de equivalencias semánticas, idiomáticas, conceptuales y culturales realizada por un comité de nueve jueces; evaluación de la comprensibilidad del instrumento por 30 especialistas en Cuidados Intensivos Pediátricos TIP; revisión de la evaluación de comprensibilidad; revisión final de la traducción; informe final. Resultados: El instrumento adaptado se dividió en 35 sentencias, siendo evaluadas por nueve jueces en cuanto a sus equivalencias. La concordancia entre los jueces en el análisis de equivalencias resultó excelente, con una puntuación media de 96,9% en la segunda vuelta. Hubo necesidad de dos rondas, ya que algunos ítems no mostraron un 80% de acuerdo en la primera etapa. En la etapa de la evaluación de comprensibilidad, se obtuvo el 100% de la comprensión de los especialistas. Conclusión: La traducción y adaptación cultural del instrumento wat-1 al idioma portugués hablado en Brasil fue considerada satisfactoria.(AU)

The hemodynamic effects of diazepam versus dexmedetomidine in the treatment of alcohol withdrawal syndrome: A randomized clinical trial / Efectos hemodinámicos del diazepam versus la dexmedetomidina en el tratamiento del síndrome de abstinencia del alcohol: ensayo clínico aleatorizado

Background: Dexmedetomidine (DEX) is an alpha-2 adrenergic drug used for short sedation and as an alternative to diazepam (DZP) in the treatment of alcohol withdrawal syndrome (AWS).PurposeThis study aims to compare the hemodynamic effect of DZP versus DEX on heart rate (HR) and blood pressure in patients with AWS.MethodsProspective randomized clinical trial that includes 40 patients with AWS from Mérida, Yucatán, México.ResultsForty patients were randomly divided into two groups: one group DZP (n=20) patients received diazepam (doses 5–20mg IV) and the other group (n=20) received DEX (dexmedetomidine infusion .2–.7mcg/kg/min). We obtained statistical significance in sedation with the DEX group in the degree of traumatic brain injury I/II (p=.003). The DEX group remained haemodynamically stable in the first 24h, the mean HR (73.85±8.39) was significant comparing both groups (p=.002). In the comparison of the figures for the DEX group with the DZP (143.85±2.30–137.95±5.62) the SBP was significant with a (p=.0001). Furthermore, DEX treatment was shorter.ConclusionAlthough DEX is not indicated for the routine treatment of AWS, this study proposes a positive effect on HR, SBP and fewer days of treatment compared to the standard DZP treatment for AWS. (AU)

Antecedentes: La dexmedetomidina (DEX) es un fármaco alfa-2 adrenérgico, utilizado para la sedación corta y como alternativa al diazepam (DZP) en el tratamiento por síndrome de abstinencia por alcohol.ObjetivosComparar el efecto hemodinámico del DZP versus la DEX en la frecuencia cardíaca (FC) y la presión arterial en pacientes con síndrome de abstinencia del alcohol.MétodosEnsayo clínico aleatorizado prospectivo en 40 pacientes con síndrome de abstinencia de alcohol, del Hospital General Agustín O’Horán Mérida, Yucatán, México.ResultadosCuarenta pacientes fueron divididos aleatoriamente en 2 grupos: grupo DZP (n=20) recibió DZP n=20 (dosis: 5-20mg IV) y el otro grupo (n=20) recibió DEX (infusión de DEX: 0,2-0,7μg/kg/min). Obtuvimos significancia estadística en la sedación con el grupo de DEX en el grado de trauma craneoencefálico I/II (p=0,003). El grupo de DEX se mantuvo hemodinámicamente estable en las primeras 24h, la media FC (73; 85±8,39) fue significativa comparando ambos grupos (p=0,002). Las cifras de PAS para el grupo DEX comparada con DZP (143; 85±2; 30-137, 95±5,62) fue significativa con a (p=0,0001). Además, el tratamiento con DEX fue de menor duración.ConclusiónAunque DEX no está indicado para el tratamiento de rutina de AWS, este estudio propone un efecto positivo hemodinámicamente sobre la FC, la PAS y menos días de tratamiento en comparación con el tratamiento estándar de DZP para el tratamiento del síndrome de abstinencia del alcohol. (AU)

Grado de disconfort del paciente crítico pediátrico y correlación con variables sociodemográficas y clínicas, analgosedación y síndrome de abstinencia. Estudio multicéntrico COSAIP (Fase 2) / Level of discomfort in critically ill paediatric patients and its correlation with sociodemographic and clinical variables, analgosedation and withdrawal syndrome. COSAIP multicentre study (Phase 2)

Introducción: Existen factores clínicos o sociodemográficos que pueden tener un impacto en el confort del paciente crítico pediátrico. El objetivo principal fue determinar el grado de disconfort de los pacientes pediátricos ingresados en las UCIP de diversos hospitales nacionales y analizar su relación con variables sociodemográficas y clínicas, sedoanalgesia y síndrome de abstinencia.Métodos: Estudio observacional, analítico, transversal y multicéntrico en 5 hospitales españoles. Se valoró el grado de analgosedación mediante el sensor BIS y las escalas de dolor adaptadas a la edad pediátrica, una vez por turno durante 24h. El grado de abstinencia se determinó con la escala Withdrawal Assessment Tool (WAT-1), una vez por turno durante 3 días consecutivos. Además, se valoró simultáneamente el grado de disconfort mediante la COMFORT Behavior Scale-versión española (CBS-ES).Resultados: Se incluyeron un total de 261 pacientes críticos pediátricos con una mediana de edad de 1,61años (RIQ=0,35-6,55). Se objetivaron puntuaciones globales de disconfort de 10,79±3,7 en el turno de mañana versus 10,31±3,3 en el de noche. Se observó asociación estadística al comparar al grupo de pacientes analgosedados con el grupo de no analgosedados en ambos turnos (χ2: 45,48; p=0,001). A la vez, también se observó una relación estadísticamente significativa (p<0,001) entre puntuaciones bajas de disconfort y menor desarrollo de síndrome de abstinencia.Conclusiones: Existe una parte de la población estudiada que padece disconfort, por lo que se hace necesario el desarrollo de protocolos específicos guiados por instrumentos válidos y testados en la práctica clínica, como la COMFORT Behavior Scale-versión española. (AU)

Introduction: There are clinical and sociodemographic factors that have an impact on the comfort of the critically ill paediatric patient. The main aim of this study was to determine the level of discomfort of paediatric patients admitted to different national hospitals, and to analyse its correlation with sociodemographic and clinical variables, analgosedation, and withdrawal syndrome.Methods: An observational, analytical, cross-sectional, and multicentre study was conducted in five Spanish hospitals. The level of analgosedation was assessed once per shift over a 24h period, using a BIS sensor, and pain with scales adapted to paediatric age population. The intensity of withdrawal syndrome was determined using the Withdrawal Assessment Tool (WAT-1) scale once per shift for 3 days. Discomfort level was simultaneous assessed using COMFORT Behaviour Scale-Spanish version (CBS-S).Results: A total of 261 critically ill paediatric patients with median age of 1.61 years (IQR=0.35-6.55) were included. An overall discomfort score of 10.79±3.7 was observed during morning compared to 10.31±3.3 observed during the night. When comparing analgosedation and non-analgosedation groups, statistically differences were found in both shifts (χ2: 45.48; P=.001). At the same time, an association was observed (P<.001) between low discomfort scores and development of withdrawal syndrome development assessed with WAT-1.Conclusions: As there is a percentage of the studied population with discomfort, specific protocols need to be developed, guided by valuated and clinically tested tools, like the COMFORT Behaviour Scale-Spanish version. (AU)

Level of discomfort in critically ill paediatric patients and its correlation with sociodemographic and clinical variables, analgosedation and withdrawal syndrome. COSAIP multicentre study (Phase 2).

INTRODUCTION: There are clinical and sociodemographic factors that have an impact on the comfort of the critically ill paediatric patient. The main aim of this study was to determine the level of discomfort of paediatric patients admitted to different national hospitals, and to analyse its correlation with sociodemographic and clinical variables, analgosedation, and withdrawal syndrome. METHODS: An observational, analytical, cross-sectional, and multicentre study was conducted in five Spanish hospitals. The level of analgosedation was assessed once per shift over a 24 h period, using a BIS sensor, and pain with scales adapted to paediatric age population. The intensity of withdrawal syndrome was determined using the Withdrawal Assessment Tool (WAT-1) scale once per shift for 3 days. Discomfort level was simultaneously assessed using COMFORT Behaviour Scale-Spanish version (CBS-S). RESULTS: A total of 261 critically ill paediatric patients with median age of 1.61 years (IQR = 0.35-6.55) were included. An overall discomfort score of 10.79 ±â€¯3.7 was observed during morning compared to 10.31 ±â€¯3.3 during the night. When comparing analgosedation and non-analgosedation groups, statistical differences were found in both shifts (χ2: 45.48; P = .001). At the same time, an association was observed (P < .001) between low discomfort scores and development of withdrawal syndrome development assessed with WAT-1. CONCLUSIONS: As there is a percentage of the studied population with discomfort, specific protocols need to be developed, guided by valuated and clinically tested tools, like the COMFORT Behaviour Scale-Spanish version.

Zolpidem Dependence and Withdrawal. A Case Report of Generalized Seizures. / Dependencia y abstinencia de zolpidem. Reporte de un caso de convulsiones generalizadas.

Zolpidem is a non-benzodiazepine hypnotic agent used most frequently in the treatment of insomnia, indicated for short-term use. It is not indicated for the chronic treatment of sleep disorders, despite which there is evidence in clinical practice that a large number of patients receive it for years. Although it has been described that it presents a better profile of adverse effects than benzodiazepines and that it generates a lower risk of dependence and withdrawal than these, there are significant reports of cases of dependence and withdrawal from zolpidem. A report of a case of generalized tonic-clonic seizures due to withdrawal at a dose of 300mg per day of zolpidem is presented and a brief review of the literature is carried out.

The hemodynamic effects of diazepam versus dexmedetomidine in the treatment of alcohol withdrawal syndrome: A randomized clinical trial.

BACKGROUND: Dexmedetomidine (DEX) is an alpha-2 adrenergic drug used for short sedation and as an alternative to diazepam (DZP) in the treatment of alcohol withdrawal syndrome (AWS). PURPOSE: This study aims to compare the hemodynamic effect of DZP versus DEX on heart rate (HR) and blood pressure in patients with AWS. METHODS: Prospective randomized clinical trial that includes 40 patients with AWS from Mérida, Yucatán, México. RESULTS: Forty patients were randomly divided into two groups: one group DZP (n=20) patients received diazepam (doses 5-20mg IV) and the other group (n=20) received DEX (dexmedetomidine infusion .2-.7mcg/kg/min). We obtained statistical significance in sedation with the DEX group in the degree of traumatic brain injury I/II (p=.003). The DEX group remained haemodynamically stable in the first 24h, the mean HR (73.85±8.39) was significant comparing both groups (p=.002). In the comparison of the figures for the DEX group with the DZP (143.85±2.30-137.95±5.62) the SBP was significant with a (p=.0001). Furthermore, DEX treatment was shorter. CONCLUSION: Although DEX is not indicated for the routine treatment of AWS, this study proposes a positive effect on HR, SBP and fewer days of treatment compared to the standard DZP treatment for AWS. Clinical Trials.gov ID: NCT03877120-https://clinicaltrials.gov/ct2/show/NCT03877120.

[Level of discomfort in critically ill paediatric patients and its correlation with sociodemographic and clinical variables, analgosedation and withdrawal syndrome. COSAIP multicentre study (Phase 2)]. / Grado de disconfort del paciente crítico pediátrico y correlación con variables sociodemográficas y clínicas, analgosedación y síndrome de abstinencia. Estudio multicéntrico COSAIP (Fase 2).

INTRODUCTION: There are clinical and sociodemographic factors that have an impact on the comfort of the critically ill paediatric patient. The main aim of this study was to determine the level of discomfort of paediatric patients admitted to different national hospitals, and to analyse its correlation with sociodemographic and clinical variables, analgosedation, and withdrawal syndrome. METHODS: An observational, analytical, cross-sectional, and multicentre study was conducted in five Spanish hospitals. The level of analgosedation was assessed once per shift over a 24h period, using a BIS sensor, and pain with scales adapted to paediatric age population. The intensity of withdrawal syndrome was determined using the Withdrawal Assessment Tool (WAT-1) scale once per shift for 3 days. Discomfort level was simultaneous assessed using COMFORT Behaviour Scale-Spanish version (CBS-S). RESULTS: A total of 261 critically ill paediatric patients with median age of 1.61 years (IQR=0.35-6.55) were included. An overall discomfort score of 10.79±3.7 was observed during morning compared to 10.31±3.3 observed during the night. When comparing analgosedation and non-analgosedation groups, statistically differences were found in both shifts (χ2: 45.48; P=.001). At the same time, an association was observed (P<.001) between low discomfort scores and development of withdrawal syndrome development assessed with WAT-1. CONCLUSIONS: As there is a percentage of the studied population with discomfort, specific protocols need to be developed, guided by valuated and clinically tested tools, like the COMFORT Behaviour Scale-Spanish version.

Diferencia entre los signos y síntomas del consumo y la abstinencia por Basuco y Cocaína: estudio piloto en Manizales, Colombia / Difference between the signs and symptoms of consumption and abstinence by Basuco y cocaine: Pilot study in Manizales, Colombia

Objetivo: el Basuco es una sustancia psicoactiva derivada de la hoja de coca; hasta ahora no se ha descrito la sintomatología que genera su consumo ni su síndrome de abstinencia, por lo que suele incluirse en el mismo grupo sindromático de la cocaína. En este estudio se pretende determinar si existen signos y síntomas característicos del Basuco. Materiales y métodos: etudio piloto de carácter descriptivo y transversal, empleando una encuesta heteroaplicada a pacientes que consumieran exclusivamente Basuco, donde se les preguntaba si habían presentado determinados signos y síntomas durante su consumo o durante el síndrome de abstinencia por Basuco. Resultados: en el consumo se encontró predominio del insomnio, hiporexia, disminución de la sensación del cansancio, delirios y aislamiento social, mientras que durante la abstinencia predominó la depresión, irritabilidad, hipersominia e hiperfagia, asociado a sensación de deterioro y deseo de abandonar el consumo. Conclusiones: la sintomatología tanto del consumo como del síndrome de abstinencia por Basuco parece tener diferencias respecto a la generada por la cocaína..(AU)

Objetive: the Basuco is a psychoactive substance derived from the coca leaf, which has not been described the symptoms that generate the consumption or withdrawal syndrome, so they are included in the same syndromic group of cocaine. This study aims to identify if there are signs and symptoms characteristic of Basuco to improve diagnostic accuracy and facilitate syndromic management. Materials and methods: bservational and cross-sectional study, using a hetero-applied survey of patients who exclusively consumed Basuco, in which they were asked if they had presented certain signs and symptoms during the intoxication or during the withdrawal syndrome by Basuco. Results: during the consumption, the insomnia, hyporexia, decreased sensation of tiredness, delusions and social isolation were predominant, while during depression abstinence, irritability, hypersomnia and hyperphagia, associated with a sense of deterioration and desire to abandon the consume were more representative. Conclutions: the symptomatology of both intoxication and withdrawal syndrome by Basuco has important differences with respect to those generated by cocaine..(AU)

Motivação para primeira experiência do uso de drogas e recaídas de pessoas em tratamento / Motivation for first-time drug use and relapses of people in treatment

O objetivo deste estudo foi investigar a motivação para primeira experiência no uso de drogas e recaídas após abstinência por pessoas com dependência química induzida pelo crack. Estudo descritivo, de abordagem mista. Foram realizadas 600 entrevistas com a utilização de questionário estruturado, na etapa quantitativa, e oito grupos focais, na etapa qualitativa, com total de 39 participantes. Para análise de dados utilizou-se o software SPSS e o método de interpretação de sentidos. A curiosidade motivou a iniciação do uso de drogas, assim como a pressão dos amigos e problemas familiares. Já a dificuldade de ficar sem a droga, vontade de sentir o efeito novamente, pressão de amigos, problemas familiares, decepção pela desconfiança dos familiares e o uso de drogas na própria instituição de tratamento foram relatados como motivadores de recaída. Os dados em ambas as metodologias foram convergentes e ratificaram os resultados obtidos.

The aim of this study was to investigate the motivation for first-time drug use and relapses after abstinence of people with chemical dependency to crack cocaine. A descriptive study, with a mixed approach. In the quantitative phase, six hundred interviews were conducted using a structured questionnaire. In the qualitative phase, eight focus groups were created, with 39 total participants. SPSS software and the sense interpretation method were used to analyze the data. Curiosity, as well as peer pressure and family problems, motivated the initiation of drug use. Difficulty to live without the drug, desire to feel its effect again, peer pressure, family problems, disappointment in lack of trust of family members, and drug use at the rehabilitation institution were reported as relapse motivators. The data in both methodologies were convergent and confirmed the obtained results.